Therapie des hepatozellulären Karzinoms

M A Wörns; R Klöckner; A Weinmann; P R Galle

doi:10.1007/s00108-013-3318-4

Therapie des hepatozellulären Karzinoms

Translated title of the contribution: Therapy of hepatocellular carcinoma

M A Wörns, R Klöckner, A Weinmann, P R Galle

Clinic of Radiology and Nuclear Medicine

Medizinische Klinik und Poliklinik I

Abstract

Today, hepatocellular carcinoma (HCC) represents the leading cause of death in patients with liver cirrhosis; in most western countries the incidence is also expected to increase further. Due to insufficient surveillance of patients at risk, most cases are diagnosed in an intermediate to advanced stage, leading-together with the underlying liver cirrhosis-to limited therapeutic options and a dismal prognosis. Therefore, classification according to stage and interdisciplinary treatment decisions in experienced centers are of paramount importance to provide an individualized treatment plan when considering potentially curative (resection, liver transplantation, local ablation) and palliative (transarterial approaches, sorafenib) treatment options. There is hope that the prognosis of patients with HCC can be improved in the near future by better prevention, stringent surveillance, multimodality treatment approaches, and an expansion of personalized medicine.

Translated title of the contribution	Therapy of hepatocellular carcinoma
Original language	German
Journal	Internist
Volume	55
Issue number	1
Pages (from-to)	23-4, 26-30
ISSN	0020-9554
DOIs	https://doi.org/10.1007/s00108-013-3318-4
Publication status	Published - 01.2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00108-013-3318-4

Cite this

@article{07e9187158e44279a21fa4f68c1ff8ef,

title = "Therapie des hepatozellul{\"a}ren Karzinoms",

abstract = "Today, hepatocellular carcinoma (HCC) represents the leading cause of death in patients with liver cirrhosis; in most western countries the incidence is also expected to increase further. Due to insufficient surveillance of patients at risk, most cases are diagnosed in an intermediate to advanced stage, leading-together with the underlying liver cirrhosis-to limited therapeutic options and a dismal prognosis. Therefore, classification according to stage and interdisciplinary treatment decisions in experienced centers are of paramount importance to provide an individualized treatment plan when considering potentially curative (resection, liver transplantation, local ablation) and palliative (transarterial approaches, sorafenib) treatment options. There is hope that the prognosis of patients with HCC can be improved in the near future by better prevention, stringent surveillance, multimodality treatment approaches, and an expansion of personalized medicine.",

author = "W{\"o}rns, {M A} and R Kl{\"o}ckner and A Weinmann and Galle, {P R}",

year = "2014",

month = jan,

doi = "10.1007/s00108-013-3318-4",

language = "Deutsch",

volume = "55",

pages = "23--4, 26--30",

journal = "Internist",

issn = "0020-9554",

number = "1",

}

TY - JOUR

T1 - Therapie des hepatozellulären Karzinoms

AU - Wörns, M A

AU - Klöckner, R

AU - Weinmann, A

AU - Galle, P R

PY - 2014/1

Y1 - 2014/1

N2 - Today, hepatocellular carcinoma (HCC) represents the leading cause of death in patients with liver cirrhosis; in most western countries the incidence is also expected to increase further. Due to insufficient surveillance of patients at risk, most cases are diagnosed in an intermediate to advanced stage, leading-together with the underlying liver cirrhosis-to limited therapeutic options and a dismal prognosis. Therefore, classification according to stage and interdisciplinary treatment decisions in experienced centers are of paramount importance to provide an individualized treatment plan when considering potentially curative (resection, liver transplantation, local ablation) and palliative (transarterial approaches, sorafenib) treatment options. There is hope that the prognosis of patients with HCC can be improved in the near future by better prevention, stringent surveillance, multimodality treatment approaches, and an expansion of personalized medicine.

AB - Today, hepatocellular carcinoma (HCC) represents the leading cause of death in patients with liver cirrhosis; in most western countries the incidence is also expected to increase further. Due to insufficient surveillance of patients at risk, most cases are diagnosed in an intermediate to advanced stage, leading-together with the underlying liver cirrhosis-to limited therapeutic options and a dismal prognosis. Therefore, classification according to stage and interdisciplinary treatment decisions in experienced centers are of paramount importance to provide an individualized treatment plan when considering potentially curative (resection, liver transplantation, local ablation) and palliative (transarterial approaches, sorafenib) treatment options. There is hope that the prognosis of patients with HCC can be improved in the near future by better prevention, stringent surveillance, multimodality treatment approaches, and an expansion of personalized medicine.

U2 - 10.1007/s00108-013-3318-4

DO - 10.1007/s00108-013-3318-4

M3 - Zeitschriftenaufsätze

C2 - 24240604

SN - 0020-9554

VL - 55

SP - 23-4, 26-30

JO - Internist

JF - Internist

IS - 1

ER -